stockrow
Saturday 7 November 2026
Export VERU’s income statement to Excel — free account
Veru Inc.
VERU Healthcare Biotechnology
Veru Inc.’s revenue for fiscal 2024 (year ended September 2024) was $16.9 million, up 3.62% from fiscal 2023.
- EPS
- +40.0%
- Free cash flow
- +0.27%
Quarter to June 2026, against a year earlier
2.14
0.08
+3.88%
Follow VERU
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (62.25%) | (49.98%) | (59.96%) | (89.74%) |
+8 more TTM periods Free account |
|
| (42.29%) | (36.84%) | (43.74%) | (50.36%) | ||
ROIC |
(464.03%) | (295.68%) | (720.95%) | (120,852.54%) | |
Return on Tangible Assets |
(63.73%) | (49.35%) | (63.68%) | (197.71%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.13) | (1.13) | (1.22) | (2.05) | |
Free Cash Flow |
(26.04) | (26.06) | (24.88) | (30.04) | |
Capital Expenditures |
— | — | — | 0.00 | |
| Other line items | |||||
Cash ROIC |
(48.08%) | (39.75%) | (34.31%) | (81.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
1.91 | 1.87 | 1.30 | 1.32 | |
Depreciation/Fixed assets |
0.40 | 0.37 | 0.34 | 0.42 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.01) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.13) | (1.13) | (1.22) | (2.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026